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ABSTRACT
Pre-mRNA splicing is catalyzed by the large
ribonucleoprotein spliceosome. Spliceosome
assembly is a highly dynamic process in which the
complex transitions through a number of intermedi-
ates. Recently, the potent anti-tumor compound
Spliceostatin A (SSA) was shown to inhibit splicing
and to interact with an essential component of the
spliceosome, SF3b. However, it was unclear
whether SSA directly impacts the spliceosome
and, if so, by what mechanism, which limits
interpretation of the drugs influence on splicing.
Here, we report that SSA inhibits pre-mRNA
splicing by interfering with the spliceosome subse-
quent to U2 snRNP addition. We demonstrate that
SSA inhibition of spliceosome assembly requires
ATP, key pre-mRNA splicing sequences and intact
U1 and U2 snRNAs. Furthermore all five U snRNAs in
addition to the SSA molecule associate with
pre-mRNA during SSA inhibition. Kinetic analyses
reveal that SSA impedes the A to B complex transi-
tion. Remarkably, our data imply that, in addition to
its established function in early U2 snRNP recruit-
ment, SF3b plays a role in later maturation of
spliceosomes. This work establishes SSA as a
powerful tool for dissecting the dynamics of
spliceosomes in cells. In addition our data will
inform the design of synthetic splicing modulator
compounds for targeted anti-tumor treatment.
INTRODUCTION
Pre-mRNA splicing plays an essential role in the expres-
sion of eukaryotic genomes. Splicing removes intervening
sequences (introns) that interrupt nearly all of human gene
transcripts. Ineﬃciency or mistakes in splicing are
implicated in an array of human diseases (1), and
modulating splicing is proving to be an eﬀective method
to treat a collection of diseases (2–4). Cells have evolved
an elaborate machine, known as the spliceosome, to carry
out the two chemical steps of the splicing reaction at each
intron. Spliceosomes assemble from key building blocks,
which include ﬁve snRNAs (U1, U2, U4, U5 and U6) and
their speciﬁc protein components (5). Together these com-
ponents play critical roles in identifying conserved splicing
signals in pre-mRNAs, assembling the catalytic
spliceosome and facilitating splicing chemistry (6).
Spliceosome formation is very complex and has been
modeled as a step-wise assembly through a number of
intermediates (7). These intermediates (E, A, B and C
complexes) were ﬁrst identiﬁed by their migration in
native gels and later deﬁned by their U snRNP compo-
nents. The ﬁrst splicing complex, early complex
(E complex), involves recognition of the 50 splice site by
U1 snRNA in an ATP-independent manner (8,9). At this
point, U2 snRNP also appears to loosely associate with E
complex (10,11). As E complex transitions to the
prespliceosome (A complex), U2 snRNP is recruited to
the branch point adenosine via interactions between the
SF3b subcomplex protein SF3b1 and U2AF
65 (12).
ATP-dependent stabilization of the interaction between
U2 snRNP and the branch point sequence is a hallmark
of A complex assembly (10). A fully assembled
spliceosome (B complex) forms with the stable incorpor-
ation of the tri-snRNP (U4/U6 U5) and Prp19 complex.
Following a series of ATP-dependent RNA:RNA and
RNA:protein rearrangements and destabilization of U1
snRNP and U4 snRNP associations, the catalytic
spliceosome (C complex) forms to carry out the two se-
quential transesteriﬁcation reactions of splicing (13–15).
In addition to the interactions noted above, there are
many more intermolecular contacts among spliceosome
components that remain to be determined. Furthermore,
with the complexity of spliceosome dynamics, regulation
and components, it is likely that many additional con-
formations of the splicing machinery exist to govern tran-
sitions between the known intermediate complexes.
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a lack of tools for arresting the spliceosome during its
dynamic assembly pathway. Small molecule inhibitors of
pre-mRNA splicing will be critical for manipulating
spliceosomes to dissect their structure and function in
the cell. A growing number of inhibitors of splicing and
spliceosome assembly have been reported (3,4,16–27),
however, the mechanism by which they exert their inﬂu-
ence on splicing is unclear.
Spliceostatin A (SSA), originally identiﬁed as an
anti-tumor compound (28), is a potent inhibitor of
in vitro and in vivo pre-mRNA splicing (24). It has been
suggested that SSA shares a pharmacophore structure
with pladienolide, another splicing inhibitor (3). Both
SSA and pladienolide have been shown to interact with
the SF3b complex, which is a component of U2 snRNP
and is essential for splicing (29,30). Although this ﬁnding
suggests that SSA may directly interfere with U2 snRNP
function, how the compound inhibits splicing remained to
be determined. Before SSA can fulﬁll its promise as a
general tool to manipulate splicing, it is necessary to
understand the molecular mechanism of SSA-mediated
splicing inhibition. Furthermore, because SSA,
pladienolide and their derivatives have been shown to dif-
ferentially inhibit a diverse collection of human tumor
lines (28,31,32) understanding the molecular eﬀects of
these splicing modulators will be important for developing
therapeutics that target-speciﬁc cancer types based on the
compounds.
In the following study, we investigated the eﬀects of
SSA on the assembly of human spliceosomes. We ﬁnd
that the compound interferes with spliceosome assembly
subsequent to stable U2 snRNP association with
pre-mRNA. SSA inhibits spliceosome assembly by
slowing the A to B complex transition, and the inhibition
requires ATP, functional snRNPs and splicing signals in
the pre-mRNA. During SSA inhibition all the U snRNAs
as well as the SSA molecule associate with pre-mRNA.
Collectively, our data suggest that SSA inhibits
spliceosome assembly at the transition between A and B
complex spliceosomes, and indicate a role for SF3b fol-
lowing U2 snRNP recruitment to the spliceosome. Our
study opens the way towards examining spliceosome
assembly at this important transition in cells.
METHODS
Plasmids and pre-mRNA in vitro transcription
For in vitro splicing reactions, we used a derivative of the
adenovirus major late (AdML) transcript that contains
three MS2 binding sites within the 30 exon with an AG
! GG 30 splice site mutation (33) as a splicing substrate
(10). To remove splicing consensus sequences, we mutated
the 50 splice site (GU ! CU) and branch point (A ! G)
of this splicing substrate. Splicing substrates were
generated by T7 runoﬀ transcription,
G(50)ppp(50)G-capped, body labeled with
32P UTP and
gel puriﬁed.
In vitro splicing reactions with SSA treated
nuclear extract
HeLa nuclear extract was incubated with 5% MeOH, or
indicated SSA concentrations for 1h at 4 C. Subsequent
in vitro splicing reactions consisted of 40% pre-treated
nuclear extract, 2nM pre-mRNA splicing substrate,
2mM MgAc, 60mM KGlu, 2mM ATP, 5mM creatine
phosphate (CP) and 0.01mg/ml yeast tRNA and were
conducted at 30 C for times indicated. For ATP depletion,
NE was pre-incubated at 30 C for 10min and ATP and
CP were omitted from the reactions. At indicated
timepoints, RNA was isolated from splicing reaction by
phenol–chloroform–isoamyl alcohol extraction and
ethanol precipitation and then separated by denaturing
urea PAGE. Splicing gels were scanned using a Typhoon
phosphorimager (Molecular Dynamics) and splicing eﬃ-
ciency calculated using Imagequant software.
Native gel analysis
To separate higher order complexes, splicing reactions
were stopped at indicated time points by placing on ice
and adding 5  native loading buﬀer (0.125mg/ml
heparin, 20mM Tris, 20mM glycine, 25% glycerol,
0.25% cyan blue, 0.25% bromophenol blue). After 5min
centrifugation at 4 C, samples were warmed to room tem-
perature and loaded onto 2.1% native agarose gels. Gels
were run in 20mM Tris/glycine at 72V for 3h and 50min.
Gels used for complex analysis were immediately dried
down on Whatman paper at 55 C for 30min and
exposed overnight before being analyzed using a
phosphorimager.
To separate E and H complexes, 1.5% native agarose
gels were used. In this case, heparin was not included with
the ATP-depleted reactions untreated with SSA.
Complex pull downs
Pre-mRNA was bound with 50 molar excess of MS2-MBP
and added to 1ml splicing reactions. Following the
indicated incubation conditions for each complex, the re-
actions were treated with 0.125mg/ml heparin for 5min at
30 C and then passed over 100ml of amlyose resin three
times at 4 C. The beads were washed extensively with
150mM KCl, 2mM MgCl2 and 20mM Tris pH 7.9.
Complexes were eluted in the same buﬀer with 10mM
maltose. Control reactions included incubating splicing
reactions in the absence of ATP for 30min at 4 C, in
the absence of ATP for 30min at 30 C, or with NE
pre-incubated with 2mMo fa2 0-O-methyl oligonucleotide
complimentary to nucleotides 1–20 of U2 snRNA (34).
SSA-inhibited spliceosomes were accumulated in splicing
reactions containing NE treated with 200nM SSA.
RNase H cleavage of U snRNAs
RNase H cleavage of U1 and U2 snRNAs was carried out
as described in ref. (35) using the following DNA oligo-
nucleotides: U1 50-TTCAGGTAAGTACTCA-30 (comple-
mentary to nucleotides 2–11) and U2 50-CAGATACTAC
ACTTG-30 (complementary to nucleotides 28–42; 35).
Digestions were veriﬁed by SYBR-Gold direct staining.
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NeutrAvidin agarose (Thermo Fisher Scientiﬁc) was
blocked with 50  Denhardt’s solution and washed with
150mM KCl, 2mM MgCl2, 20mM Tris pH 7.9. The
beads were then incubated in splicing reactions containing
200nM biotinylated SSA or non-biotinylated SSA and
then washed with the same buﬀer. Total input and
pre-mRNA in the unbound fraction, washes and bound
fractions were measured using a Geiger counter.
Pre-mRNA remaining on beads was quantiﬁed by
comparing bound pre-mRNA c.p.m. counts to c.p.m.
counts from total input, unbound fraction and wash
fractions.
RESULTS
Spliceostatin A interferes with spliceosome assembly
subsequent to A complex formation
SSA is an established inhibitor of splicing chemistry;
however, whether the inhibition is due to an arrest of
spliceosome assembly or to another indirect mechanism
remained to be explored. Kaida et al. (24) identiﬁed the
U2 snRNP subunit SF3b as a molecular target of SSA
(24). SF3b complex plays an essential role in the
ATP-dependent stable addition of U2 snRNP to E
complex and it is critical for the assembly of
prespliceosomes (36,37). We initially hypothesized that
the binding of SSA to SF3b would interfere with U2
snRNP addition, leading to an arrest of spliceosome
assembly at a point similar to E complex. To test this
hypothesis we ﬁrst conﬁrmed that SSA inhibits splicing
on our model substrate, a derivative of the adenovirus
major late (AdML) pre-mRNA (13,38), by conducting
in vitro splicing reactions in HeLa nuclear extract (NE)
in the presence of increasing concentrations of SSA. It
was previously reported that SSA blocks splicing before
the ﬁrst transesteriﬁcation reaction (24). Similarly, relative
to extracts treated with 5% MeOH, we observe <1% of
splicing eﬃciency at the ﬁrst step of chemistry when NE is
treated with 200nM SSA with our model substrate
(Figure 1A).
To analyze SSA’s eﬀect on spliceosome assembly, we
treated NE with SSA and used it for in vitro assembly of
splicing complexes, which were then separated on 2.1%
native agarose gels. These gels allow for the separation
of the E!A!B!C spliceosome intermediates. With
increasing concentrations of SSA, we clearly observe loss
of higher order splicing complexes (Figure 1B).
Surprisingly, in reactions treated with higher concentra-
tions of SSA we observe accumulation of a pre-mRNA
containing complex that migrates at a position near A
complex spliceosomes (Figure 1B). Accumulation of this
complex is proportional to the loss of higher order splicing
complexes. At lower concentrations of SSA, B complex
readily forms, but at concentrations of the drug that
strongly inhibit splicing we see complete loss of B and C
complexes. These data suggest that SSA inhibits assembly
of catalytically competent spliceosomes subsequent to A
complex formation.
SSA inhibits spliceosome assembly following
E complex formation
We next questioned whether the complex that forms on
pre-mRNA in the presence of SSA represents an
Figure 1. SSA inhibits spliceosome assembly: (A) denaturing PAGE
analysis RNA from 25min in vitro splicing reactions using an AdML
splicing substrate in NE treated with indicated concentrations of SSA.
We note that the substrate contains an AG ! GG 30 splice site
mutation, which blocks splicing prior to exon ligation. We ﬁnd that
SSA does not impact the second step of splicing on wild-type substrates
(Supplementary Data S1.) Splicing products schematized from top to
bottom are lariat intermediate, pre-mRNA and mRNA. The total
percent ﬁrst step splicing activity (ﬁrst step products/total RNA)
indicated below each lane was normalized to 5% MeOH control
splicing reaction. (B) Native agarose gel (2.1%) analysis of in vitro
splicing reactions shown in (A). The 30-splice site mutant accumulates
C complex spliceosomes and allows better quantiﬁcation of the diﬀer-
ent spliceosome assembly intermediate complexes. The position of C, B,
A and H/E splicing complexes and SSA-inhibited spliceosomes are
indicated. The ratio of B/A complex is indicated below each lane.
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complex that forms independent of splicing. If the
complex that accumulates with SSA treatment is a
spliceosome intermediate, its migration in the native gels
suggests that it is an A-like complex. A complex formation
is preceded by E complex, but in the gels described above
(2.1% native gels) we cannot diﬀerentiate E complex from
H complex, which is the collection of proteins that asso-
ciate with RNA in NE in the absence of splicing (39). To
assess E complex formation in the presence of SSA, we
analyzed a time course of spliceosome assembly on 1.5%
native agarose gels, which separate E from H complex. In
control reactions depleted of ATP, we observe the
expected accumulation of E complex by 4min. In reac-
tions treated with SSA in the presence of ATP, E
complex still assembles within 4min. Moreover, E
complex appears to progress to a stable higher order
arrested complex by 15min (Figure 2). These data are
consistent with the complex that assembles in the
presence of SSA being a spliceosome complex intermedi-
ate that transitions through E complex.
SSA inhibition of spliceosome assembly follows an
ATP- dependent step
Following E complex, the next intermediate of normal
spliceosome assembly is A complex, the formation of
which requires ATP hydrolysis. Previous studies
demonstrated that the stable addition of U2 snRNP
underlies the ATP dependence of A complex assembly
(12,36,37). If SSA inhibits spliceosome assembly following
E complex, the observed drug-induced arrest of assembly
should also exhibit a dependence on ATP. To address this
issue, we carried out splicing reactions in NE treated with
200nM SSA in the presence or absence of ATP and
analyzed complex assembly on native agarose gels
(Figure 3A). In contrast to ATP-containing reactions,
we do not detect formation of the drug-inhibited
complex in ATP-depleted reactions. This result implies
that SSA inhibits spliceosome assembly subsequent to
the ATP-dependent stabilization of U2 snRNP.
SSA inhibition of spliceosome assembly requires
a5 0 splice site and branch point
Spliceosome assembly is guided by consensus sequences
within the pre-mRNA substrate including 50 splice site,
30 splice site and branch point. If SSA is speciﬁcally in-
hibiting spliceosome assembly, formation of the
drug-inhibited complex should be dependent upon
conserved splicing signals. Figure 3A shows an SSA-
inhibited complex forms on a substrate lacking a 30
splice site. This result indicates that SSA inhibits
spliceosome assembly before the 30 splice site is required,
which is during C complex formation with our model sub-
strate. In contrast, when we carried out splicing reactions
in the presence of SSA using a pre-mRNA substrates with
mutant 50 and 30 splice sites or 50 splice site mutation
alone, the SSA-inhibited complex no longer forms
(Figure 3B). Furthermore, the complex does not accumu-
late on a pre-mRNA with mutant branch point and 30
splice site (Figure 3C). These data show that while the 30
splice site is expendable for the assembly of the
drug-inhibited complex, the 50 splice site and branch
point are necessary. From these results, we conclude
that the observed drug-inhibited complex is likely a
splicing complex because it has the same splicing
sequence requirements as spliceosomes. We also
conclude that SSA inhibits spliceosome assembly at a
point following recognition of the 50 splice site and
branch point sequences. Given that the only demonstrated
role for SF3b to date is in recognition of the branch point,
this result also suggests that SSA may interfere with a
subsequent function of SF3b in spliceosome assembly.
SSA inhibition of spliceosome assembly is dependent on
functional U1 and U2 snRNPs
If the association of U snRNPs with pre-mRNA is
relevant to SSA inhibition of splicing, then we expect for-
mation of the drug-inhibited splicing complex to be de-
pendent on U snRNP functionality. We looked at the
roles of the U snRNPs by digesting key RNA sequences
within U1 and U2 and assessed the subsequent eﬀects on
SSA inhibition by native gel analysis. We targeted regions
in U1 and U2 snRNAs with DNA oligonucleotides to
trigger RNase H cleavage, which is known to inhibit
splicing (35). After verifying digest of speciﬁc snRNAs
in nuclear extract (Supplementary Data S3), we used
those extracts for spliceosome assembly with and
without SSA treatment (Figure 3D). In untreated
extracts in which U1 (U1) or U2 (U2) were digested,
A complex spliceosomes failed to assemble. Likewise the
drug-inhibited splicing complex forms much less eﬃciently
Figure 2. SSA inhibits spliceosome assembly following E complex for-
mation: native agarose gel (1.5%) analysis of in vitro splicing reactions
±ATP and ±200nM SSA.
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data indicate functional U1 and U2 snRNAs are required
prior to SSA inhibition, likely in the same roles that they
play in normal spliceosome assembly.
SSA slows the transition of A to B complex spliceosomes
We performed a kinetic analysis of spliceosome assembly
at saturating and sub-saturating concentrations of SSA to
better determine the assembly step at which SSA exerts its
inﬂuence. In the absence of SSA the appearance of A
complex by 1min is followed by the formation of B
complex, which begins to accumulate after 5min. C
complex is readily apparent after 15min (Figure 4A). At
saturating concentrations of SSA we observe only H/E
complex at 0min, with SSA-inhibited spliceosomes
accumulating by 4 min. We detect no progression to
higher-order complexes. This result suggests that at
saturating concentrations of SSA, progress to A complex
may be slowed.
We conducted a time course at a sub-saturating concen-
tration (75nM) of SSA to more closely examine the
stage(s) at which SSA aﬀects spliceosome assembly. At
this concentration, splicing is inhibited but not completely
blocked. Under these conditions, we see that A complex
forms with kinetics similar to untreated extracts, whereas
the transition of A to B complex is slowed relative to no-
drug condition. The rate of transition of B to C complex is
largely unchanged (Figure 4B). We quantiﬁed the transi-
tion of A to B complexes in each of the conditions
by determining the B/A ratio at each time point
(Figure 4G). This analysis indicates a consistent slowing
of the rate of A to B complex transition such that the
limited assembly of B complex appears to be the
primary consequence of SSA inhibition.
U1, U2 and tri-snRNP snRNAs associate with pre-mRNA
during SSA inhibition of spliceosome assembly
Spliceosome assembly is modeled as an ordered addition
of U snRNPs to pre-mRNA (7). Knowing the constella-
tion of U snRNPs that associate with pre-mRNA in the
presence of SSA will allow us to further deﬁne the mech-
anism of SSA inhibition of spliceosome assembly. We
investigated the association of snRNAs with pre-mRNA
during SSA inhibition by pull-down experiments. For the
pull downs, we employed a pre-mRNA substrate bound
by a fusion of MS2 coat protein and maltose binding
protein (MS2:MBP). Following SSA inhibition of
splicing with this substrate, we incubated the splicing re-
actions with amylose beads, washed extensively and eluted
tagged pre-mRNA with maltose. To identify the U
snRNAs associated with the drug-inhibited splicing
complex, we isolated RNA from peak elution fractions,
which was then separated in denaturing PAGE gels and
stained with SYBR-Gold (Figure 5A). For comparison,
we repeated pull downs from reactions in which we
blocked spliceosome assembly by incubating splicing reac-
tions on ice without ATP, at 30  without ATP or in the
presence of a 20-O-methyl oligonucleotide that hybridizes
to the 50-end of U2 snRNA (34; Figure 5A). We used
reactions held at 4  with no ATP as a control for the
background association of snRNAs to our pre-mRNA
substrate. As expected in the absence of ATP at 30 ,w e
observe U1 and U2 snRNAs in pre-mRNA pull downs
(10). Previously, Lamond et al. (34) demonstrated that
the U2-directed oligo blocks the transition of A to B
complex spliceosomes, and when NE is treated with this
oligo we observe association of U1 and U2 snRNAs with
pre-mRNA. In contrast, in pre-mRNA pull downs from
SSA-inhibited splicing reactions we see a very strong band
for U2 as well as distinct bands for U1, U4, U5 and U6
Figure 3. SSA inhibition of spliceosome assembly follows an ATP-dependent step and requires splicing signals and functional U1 and U2 snRNPs:
(A) native agarose gel (2.1%) analysis of in vitro splicing reactions ±ATP and ±200nM SSA as indicated. (B) Native agarose gel (2.1%) analysis of
in vitro splicing reactions using pre-mRNA substrates that are wild-type (WT) or that contain both mutant 50 and 30 splice sites (50/30) or mutant
50 splice site alone (50). Reactions were performed with NE treated with 200nM SSA at the indicated time points. (C) Same as (B) but with a
splicing substrate containing mutant branch point and 30 splice site (BP/30). (D) Native agarose gel (2.1%) analysis of 30min time points of
in vitro splicing reactions with nuclear extracts pre-incubated with DNA oligos complementary to U1 snRNA (U1), U2 snRNA (U2) or mock
(M) for RNase H-mediated digestion of the targeted snRNA and ±200nM SSA. Schematics of experimental splicing substrates are provided for
each experimental condition.
6668 Nucleic Acids Research, 2010,Vol.38, No. 19snRNA. In order to directly compare the association of
snRNAs between the diﬀerent samples, we normalized the
amounts of each snRNA relative to pre-mRNA
and deﬁned the pre-mRNA:U1 ratio as one for the 30 
no-ATP pull down (Figure 5B). The quantiﬁcation
conﬁrms that the pre-mRNA pull down from SSA-
inhibited reactions is enriched for all of the snRNAs
relative to control preparations. We note that the
Figure 4. SSA slows the transition of A to B complex spliceosomes: 2.1% native agarose gels of time courses of spliceosome assembly in splicing
reactions treated with either 5% MeOH (A), 75nM SSA (B) or 200nM SSA (C). (D–F) Relative amounts of A, B and C complexes were quantiﬁed
from gels shown in (A, B and C), respectively and plotted versus time. (G) Ratio of B/A complex was quantiﬁed and plotted versus time for each
condition tested.
Figure 5. U snRNAs associate with pre-mRNA during SSA inhibition of spliceosome assembly. (A) SYBR-Gold direct staining of nucleic acid
isolated from pull downs of spliceosomes assembled in NE treated under the following conditions: (i) 4 C, no ATP, (ii) 30 C, no ATP, (iii) anti-U2
20 O-methyl oligonucleotide+ATP or (iv) 200nM SSA+ATP. (B) Quantiﬁcation of snRNAs detected within isolated spliceosome complexes
normalized to pre-mRNA. We deﬁned the pre-mRNA:U1 ratio as one for the 30  no-ATP pull down in order to compare between pull downs.
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each other, are relatively lower than those of U1 and U2.
This observation may reﬂect a looser association of the
tri-snRNP snRNAs with SSA-inhibited spliceosomes,
such that a proportion of the tri-snRNAs are lost during
washing of the beads. This supposition is supported by the
recent ﬁndings that tri-snRNP initially associates with the
spliceosome in an unstable manner before being stably
integrated to form B complex (40,41). To conﬁrm these
results, we isolated RNA from the drug-inhibited complex
band in native gels and see by northern analysis a similar
enrichment of U2, U4, U5 and U6 snRNAs relative to
the snRNAs present in an H/E band (Supplementary
Data S2).
The interaction of SSA with pre-mRNA parallels
U2 addition
Given that SSA does not interfere with U2 association
with pre-mRNA and that the molecular target of SSA is
the SF3b complex of U2 snRNP, it is possible that SSA is
directly interfering with spliceosome assembly following
U2 snRNP addition. If so, we predicted that SSA
should be present in the drug-inhibited splicing complex.
To investigate this possibility, we employed a biotinylated
derivative of SSA (bio-SSA; 24). First we tested bio-SSA
for its eﬀect on in vitro splicing and spliceosome assembly.
Although the in vivo activity of bio-SSA is  20-fold
weaker than SSA (24), we observe no measurable diﬀer-
ence in its inhibition of in vitro splicing (Figure 6A). The
weaker in vivo activity may be due to lower membrane
permeability for bio-SSA. Notably, in the presence of
bio-SSA, a complex identical to that observed with
non-biotinylated SSA accumulates (data not shown).
We tested whether SSA associates with pre-mRNA
during SSA inhibition by inhibiting splicing with
bio-SSA and then incubating the reactions with
streptavidin beads. After washing the beads, we
compared the amount of pre-mRNA-bound streptavidin
beads from reactions containing non-biotinylated SSA
and see a signiﬁcant and reproducible increase in
pre-mRNA binding from reactions with bio-SSA
(Figure 6B). Notably, the amount of pre-mRNA bound
is 2-fold higher when ATP is included in the assembly
reaction. In contrast, when we repeated the pull-down ex-
periment with a pre-mRNA containing a mutated branch
point in the presence of ATP, we see no enrichment of
pre-mRNA with bio-SSA versus non-biotinylated SSA.
These data support that SSA is present within
SSA-inhibited spliceosomes and that its stable association
with pre-mRNA is an ATP- and branchpoint-dependent
event, like its U2 snRNP target.
DISCUSSION
SSA is one of a limited number of established inhibitors of
pre-mRNA splicing reported (3,4,16–27). SSA is the only
compound to work in the low nanomolar range and holds
great promise as a tool for studying splicing in vitro and
in vivo. Kaida et al. (24) previously demonstrated that SSA
binds the U2 snRNP SF3b complex, making it one of the
ﬁrst small molecules known to target a spliceosome com-
ponent. Understanding the mechanism of SSA inhibition
of splicing is fundamentally important for accurately
interpreting experiments using SSA to manipulate the
splicing process. Furthermore, because SSA represents
an exciting lead compound for the development of
Figure 6. Biotinylated SSA (b-SSA) associates with pre-mRNA in an ATP-dependent manner. (A) Denaturing PAGE analysis of in vitro splicing
reactions using an AdML splicing substrate containing a 30 splice site mutation with increasing b-SSA and quantiﬁed as in Figure 1A.
(B) Streptavidin agarose bead pull downs of pre-mRNA from in vitro splicing reactions containing 200nM SSA or bio-SSA±ATP. Pre-mRNA
binding is indicated as the average percentage c.p.m. of total input radioactivity retained on beads from triplicate experiments. BP is the same
pre-mRNA except containing a branch point mutation.
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action will certainly inform future studies concerning
SSA derivatives and their potential as cancer therapeutics.
This report provides a detailed description of the
kinetics, associations and dependencies of the eﬀect of
SSA on splicing and illuminates the mechanism by
which SSA inhibits the spliceosome. One of our conclu-
sions is that that SSA directly inhibits spliceosome
assembly. In the presence of SSA, a complex that shares
the same requirements as spliceosomes forms on pre-
mRNA. SSA-inhibited spliceosomes do not form in the
absence of a 50 splice site, branch point adenosine
or ATP and require functional U1 and U2 snRNAs
(Figure 7).
Second, the data show that SSA does not inhibit
splicing by blocking U2 snRNP association with
pre-mRNA. In fact, we see more U2 snRNA associate
with pre-mRNA in SSA inhibited reactions relative to
control preparations. These data suggest that SSA may
lead to a hyper-stabilization of U2 snRNP. In combin-
ation with the previously noted dependencies, our data
show that SSA directly interferes with spliceosome matur-
ation after U2 snRNP has stably integrated into the
complex.
Finally, we conclude that SSA interferes with the tran-
sition of prespliceosomes to B complex. Our kinetic data
reveal that while formation of pre-spliceosomes is
somewhat slowed at high concentrations of SSA, at
sub-saturating concentrations, SSA most strongly
impacts formation of fully assembled B complex. This
conclusion is also supported by the apparent accumula-
tion of an A-like complex in the presence of SSA. The
pre-spliceosome to B complex transition is hallmarked
by the recruitment and stable incorporation of the
tri-snRNP to pre-spliceosomes (42,43). We see that
tri-snRNP interacts with the drug-inhibited complexes,
but because those complexes do not migrate as a stable
B complex in native gels, our data suggest that while SSA
does not prevent association of tri-snRNP with the
spliceosome, it may interfere with its stable integration.
Given that SSA targets SF3b, it is reasonable to suspect
that its inhibition of splicing is mediated through SF3b.
SF3b has been shown to interact with the branch point
adenosine and to be required for the recruitment of U2
snRNP to the spliceosome (12). Our data argue that SSA
does not interfere with this established function in U2
snRNP recruitment to the spliceosome. Instead the data
suggest that SF3b may participate in an important
interaction and/or promote a conformation necessary for
the transition of A to B complex spliceosomes. The fact
that SF3b has been shown to crosslink to pre-mRNA in B
and C complex spliceosomes supports this potential role
(12). Future studies to characterize the composition,
intra-molecular interactions and structure of the splicing
complex that accumulates in the presence of SSA may
provide insight into this poorly understood transition
and into the role of the SF3b subunit following U2
snRNP recruitment to the spliceosome.
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